Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pamrevlumab

Generic Name: Pamrevlumab

Drug Type: Biotech

CAS Number: 946415-13-0

Unique Ingredient Identifier: QS5F6VTS0O

Overview

Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

Background

Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

Phase 2

Completed

Posted: 2022/03/02

Sponsor:Fondazione Policlini...

ID:NCT05262309

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Phase 3

Terminated

Posted: 2020/11/17

Sponsor:FibroGen

ID:NCT04632940

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Phase 2

Terminated

Posted: 2020/06/16

Sponsor:FibroGen

ID:NCT04432298

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Terminated

Posted: 2020/06/05

Sponsor:FibroGen

ID:NCT04419558

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Phase 3

Terminated

Posted: 2020/05/01

Sponsor:FibroGen

ID:NCT04371666

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Pamrevlumab Plus Chemotherapy Fails to Improve Survival in Advanced Pancreatic Cancer

4 months ago

The phase 3 LAPIS trial evaluated pamrevlumab in combination with chemotherapy for locally advanced, unresectable pancreatic cancer.

Rethinking Clinical Trial Endpoints for Duchenne Muscular Dystrophy

5 months ago

Current accelerated approval pathways for Duchenne muscular dystrophy (DMD) drugs rely on short-term studies with young, ambulatory patients, potentially overlooking long-term cardiorespiratory benefits.

DMD Pipeline Shows Promise with Over 75 Therapies in Development

7 months ago

Over 75 drugs are in development for Duchenne Muscular Dystrophy (DMD), targeting various mechanisms and routes of administration.

Insights from Failed IPF Trials Highlight Need for Adaptive Designs and Patient-Focused Outcomes

9 months ago

Analysis of recent idiopathic pulmonary fibrosis (IPF) trial failures emphasizes the importance of learning from setbacks to refine future clinical trial designs.

FibroGen Terminates Pamrevlumab Development After Failed Pancreatic Cancer Trials, Announces Major Workforce Reduction

10 months ago

FibroGen's lead drug pamrevlumab fails to demonstrate survival benefits in two pivotal pancreatic cancer trials, leading to complete termination of the program.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy